Bladder Cancer

Dr Terence Friedlander explains safety and efficacy data from the CheckMate 247 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC.

Terence Friedlander, MD, reviews the available adjuvant therapy options for patients with stage II or III MIBC who previously underwent bladder removal surgery.

Dr Terence Friedlander defines cisplatin eligibility in patients with MIBC and discusses how many patients receive neoadjuvant cisplatin and the treatment approaches if a patient is ineligible.

Terence Friedlander, MD, presents the case of a 75-year-old patient with stage IIIA muscle-invasive bladder cancer (MIBC) for review, and explains how patients are risk-stratified.

For patients with locally advanced or metastatic urothelial cancer, the FDA has accepted for priority review supplemental biologics license applications for enfortumab vedotin-ejfv and pembrolizumab.

Patients with low-grade upper tract urothelial cancer elicited a clinical benefit at the end of the phase 3 OLYMPUS study when treated with UGN-101.

The phase 1 INSIGHT-005 trial will further evaluate the combination of eftilagimod alpha and avelumab in patients with metastatic urothelial cancer.

New phase 3 data has led to Genentech removing the US indication of atezolizumab for treatment of patients ineligible for cisplatin chemotherapy with metastatic urothelial carcinoma.

During a Targeted Oncology case-based roundtable event, Daniel Petrylak, MD, discussed with participants the case of a patient with bladder cancer who has lung metastases and significant pulmonary comorbidities.

Results from the ARIES trial continue to show the benefit of avelumab monotherapy as a first-line drug for patients with metastatic urothelial cancer with PD-L1 expression.

During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed with participants their approaches to therapy for a patient whose bladder cancer progresses after receiving chemotherapy and immunotherapy.

Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.

Jonathan E. Rosenberg, MD, discusses what has been previously shown with enfortumab vedotin for patients with locally advanced metastatic urothelial cancer.

In an interview with Targeted Oncology, Philippe Barthelemy, MD, discussed the preliminary findings of the AVENANCE trial of avelumab in patients with advanced or metastatic urothelial carcinoma.

In an interview with Targeted Oncology, Jeanny B. Aragon-Ching, discussed recent updates from the JAVELIN Bladder 100 trial. She also discussed ongoing research involving the novel agent EV-103 in patients with advanced or metastatic urothelial cancer.

The combination of toripalimab and chemotherapy displayed promising efficacy results in a phase 2 study.

Jonathan E. Rosenberg, MD, discusses what the frontline treatment landscape for metastatic urothelial cancer currently looks like.

In an interview with Targeted Oncology, Jonathan Rosenberg, MD, further discussed the background and results of the EV-103 study in patients with locally advanced metastatic urothelial cancer.

The combination of enfortumab vedotin plus pembrolizumab led to a confirmed overall response rate of 64.5% in patients with metastatic urothelial cancer.

Multiple blood-based biomarkers suggest potential responses to treatment with maintenance avelumab for patients with advanced or metastatic urothelial carcinoma from the phase 3 JAVELIN Bladder 100 trial, according to an exploratory analysis presented at the European Society for Medical Oncology Congress 2022.

Sumanta K. Pal, MD, discusses the safety and efficacy results of the COSMIC-021 clinical trial.

The PARP inhibitor rucaparib was shown to improve progression-free survival in a cohort of the ATLANTIS study platform for metastatic urothelial carcinoma.

During the 2022 Debates and Didactics in Hematology and Oncology conference, Bassel Nazha, MD, MPH and Jacqueline T. Brown, MD, debated on adjuvant vs neoadjuvant systemic therapy for patients with upper tract urothelial cancer.

Sam S. Chang, MD, MBA, discusses the methods and design of the QUILT 3032 study.

Sophia Kamran, MD, discusses future roles that radiation oncology will play in combination with resection and targeted therapy in urothelial carcinoma.

The FDA has accepted the biologics license application for N-803 as a treatment for patients with Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.

Results from a phase 3 study of pembrolizumab and nadofaragene firadenovec in patients with BCG-unresponsive non–muscle invasive bladder cancer suggests that immune checkpoint inhibitors have synergy with antibody drug conjugates.

In an interview with Targeted Oncology, Vignesh Packiam, MD, discussed the research of gemcitabine plus cabazitaxel and pembrolizumab in patients with non-muscle invasive urothelial carcinoma who are unresponsive to docetaxel.

The development of vicineum for the treatment of patients with high-risk, Bacillus Calmette-Guerin-unresponsive non–muscle invasive bladder cancer has been voluntarily paused.

In an interview with Targeted Oncology, Matthew T. Campbell, MD, examined the positive phase 1 study results of infigratinib for the treatment of patients with localized upper tract urothelial cancer.